Show simple item record

dc.contributor.authorAhimastos, A.
dc.contributor.authorWalker, P.
dc.contributor.authorAskew, C.
dc.contributor.authorLeicht, A.
dc.contributor.authorPappas, E.
dc.contributor.authorBlombery, P.
dc.contributor.authorReid, Christopher
dc.contributor.authorGolledge, J.
dc.contributor.authorKingwell, B.
dc.identifier.citationAhimastos, A. and Walker, P. and Askew, C. and Leicht, A. and Pappas, E. and Blombery, P. and Reid, C. et al. 2013. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial. JAMA - Journal of the American Medical Association. 309 (5): pp. 453-460.

Importance: Approximately one-third of patients with peripheral artery disease experience intermittent claudication, with consequent loss of quality of life. Objective: To determine the efficacy of ramipril for improving walking ability, patient-perceived walking performance, and quality of life in patients with claudication. Design, Setting, and Patients: Randomized, double-blind, placebo-controlled trial conducted among 212 patients with peripheral artery disease (mean age, 65.5 [SD, 6.2] years), initiated in May 2008 and completed in August 2011 and conducted at 3 hospitals in Australia. Intervention: Patients were randomized to receive 10 mg/d of ramipril (n=106) or matching placebo (n=106) for 24 weeks. Main Outcome Measures: Maximum and pain-free walking times were recorded during a standard treadmill test. The Walking Impairment Questionnaire (WIQ) and Short-Form 36 Health Survey (SF-36) were used to assess walking ability and quality of life, respectively. Results: At 6 months, relative to placebo, ramipril was associated with a 75-second (95% CI, 60-89 seconds) increase in mean pain-free walking time (P<.001) and a 255-second (95% CI, 215-295 seconds) increase in maximum walking time (P<.001). Relative to placebo, ramipril improved the WIQ median distance score by 13.8 (Hodges-Lehmann 95% CI, 12.2-15.5), speed score by 13.3 (95% CI, 11.9-15.2), and stair climbing score by 25.2 (95% CI, 25.1-29.4) (P<.001 for all). The overall SF-36 median Physical Component Summary score improved by 8.2 (Hodges-Lehmann 95% CI, 3.6-11.4; P=.02) in the ramipril group relative to placebo. Ramipril did not affect the overall SF-36 median Mental Component Summary score. Conclusions and Relevance: Among patients with intermittent claudication, 24-week treatment with ramipril resulted in significant increases in pain-free and maximum treadmill walking times compared with placebo. This was associated with a significant increase in the physical functioning component of the SF-36 score. Trial Registration: Identifier: NCT00681226 ©2013 American Medical Association. All rights reserved.

dc.titleEffect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial
dc.typeJournal Article
dcterms.source.titleJAMA - Journal of the American Medical Association
curtin.departmentDepartment of Health Policy and Management
curtin.accessStatusOpen access via publisher

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record